Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 dose-schedule immunogenicity study in HIV-positive women
2018-000228-33Phase 4Active
- Sponsor
- Saint-Pierre University Hospital
- Start
- Jan 2018
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Saint-Pierre University Hospital. Primary endpoints: Seroconversion rate by HPV genotype at month 7 and Non-inferiority of Arm A versus Arm B. Started Jan 2018; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2018-000228-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000228-33.